At-Home brain zaps show promise for depression relief
NCT ID NCT07228468
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a safe, non-invasive brain stimulation treatment called tDCS that people can use at home to ease depression. About 438 adults with major depression will either receive active tDCS plus their usual care, or just usual care alone. The goal is to see if adding tDCS reduces depressive symptoms more than standard treatment alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 438 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults aged 18 years or over 2. Current episode of depression based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (APA, 2013) for major depressive disorder (MDD) as assessed by structured clinical assessment, Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) 3. Having at least a moderate severity of depressive symptoms as measured by a score of at least 18 in MADRS 4. Either not taking antidepressant medication or taking a stable dose of antidepressant medication for at least 6 weeks before enrolment. 5. Either not currently in psychotherapy or in ongoing psychotherapy for at least 6 weeks before enrolment. 6. Being under the care of GP 7. Agreeable for GP to be regularly informed about study participation 8. Able to provide written, informed consent Exclusion Criteria: 1. Significant suicide risk as measured by answering 'yes' to questions 4, 5 or 6 on the Columbia Suicide Severity Rating Scale (C-SSRS) Screen (Posner et al., 2011) 2. Primary comorbid psychiatric disorder (e.g. obsessive compulsive disorder) based on DSM-5 criteria as assessed in MINI 3. Current daily use of medications that affect cortical excitability (e.g. benzodiazepines) 4. Current illicit drug use or heavy alcohol use with high risk of alcohol use disorder as measured by a score of 8 or more in Alcohol use disorders identification test consumption (AUDIT C) (Khadjesari et al., 2017; NICE, 2023) 5. History of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), or other brain stimulation 6. History of esketamine / ketamine for treatment of depression 7. History of psychosurgery for depression 8. Having cognitive impairment (e.g. dementia) 9. Current medical disorder or neurological disorder that may mimic mood disorder (e.g. hormonal disorder, unstable heart disease) 10. Have any implant in the brain or neurocranial defect 11. Have shrapnel or any ferromagnetic material in the head 12. Have any active implantable medical device (e.g. pacemaker) 13. If female and of child-bearing potential, currently pregnant or planning to become pregnant during the study 14. Concurrent enrolment in another interventional study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cardiff and Vale Health Board
NOT_YET_RECRUITINGCardiff, CF24 4HQ, United Kingdom
-
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust
NOT_YET_RECRUITINGNewcastle, NE4 5PL, United Kingdom
-
Hampshire and Isle of Wight Healthcare NHS Foundation Trust
NOT_YET_RECRUITINGSouthampton, SO14 3DT, United Kingdom
-
Northamptonshire Healthcare NHS Foundation Trust
NOT_YET_RECRUITINGNorthampton, NN5 6UD, United Kingdom
-
Nottinghamshire Healthcare NHS Foundation Trust
NOT_YET_RECRUITINGNottingham, NG7 2UH, United Kingdom
-
South London and Maudsley NHS Foundation Trust
RECRUITINGLondon, SE5 8AF, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a structured care pathway lift teen depression in primary care?
- Can Anti-Inflammatory drugs lift depression that Won't budge?
- A brain stimulation trial aims to rewire the circuit behind depression
- Can pairing ketamine with talk therapy beat depression alone?
- Genetic matchmaking for antidepressants: a global trial puts personalization to the test
- Could a common vitamin lift depression in young people?